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This multicentre phase II study evaluated the efficacy and safety of preoperative capecitabine plus oxaliplatin and radiotherapy (RT) in
patients with locally advanced rectal cancer (T3/T4 rectal adenocarcinoma with or without nodal involvement). Treatment consisted
of one cycle of XELOX (capecitabine 1000mgm
 2 bid on days 1–14 and oxaliplatin 130mgm
 2 on day 1), followed by RT (1.8Gy
fractions 5 days per week for 5 weeks) plus CAPOX (capecitabine 825mgm
 2 bid on days 22–35 and 43–56, and oxaliplatin
50mgm
 2 on days 22, 29, 43 and 50). Surgery was recommended 5 weeks after completion of chemoradiotherapy. The primary
end point was pathological complete tumour response (pCR). Sixty patients were enrolled. In the intent-to-treat population, the pCR
rate was 23% (95% CI: 13–36%). 58 patients underwent surgery; R0 resection was achieved in 57 (98%) patients, including all 5
patients with T4 tumours. Sphincter preservation was achieved in 49 (84%) patients. Tumour and/or nodal downstaging was
observed in 39 (65%) patients. The most common grade 3/4 adverse events were diarrhoea (20%) and lymphocytopaenia (43%).
Preoperative capecitabine, oxaliplatin and RT achieved encouraging rates of pCR, R0 resection, sphincter preservation and tumour
downstaging in patients with locally advanced rectal cancer.
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In recent years, considerable progress has been made in the
treatment of locally advanced rectal cancer, mainly due to
improvements in the type and quality of surgery, better staging
methods and regular use of chemoradiation (CRT) or radiation
therapies. Although the use of preoperative CRT for resectable
rectal cancer remains a controversial issue, preoperative CRT is
clearly preferred when tumour shrinkage is required before
surgery, that is, in locally advanced T4 disease and low-lying
tumours when sphincter preservation is attempted (Sauer et al,
2004; Bosset et al, 2006; Ge ´rard et al, 2006). Furthermore,
preoperative CRT improves local disease control with less toxicity
compared with postoperative CRT (Sauer et al, 2004).
Many attempts have been made to increase the convenience and
activity of preoperative 5-fluorouracil (5-FU)-based CRT. Evidence
from phase II trials suggests that the oral fluoropyrimidine
capecitabine (Xeloda
s; F Hoffmann-La Roche Ltd, Basel,
Switzerland) has similar activity to that of protracted 5-FU
infusional CRT regimens (Glynne-Jones et al, 2006a). Combining
different chemotherapy agents, such as oxaliplatin or irinotecan,
with fluoropyrimidines has a clear rationale based on a plethora of
data in the metastatic colorectal setting and the potential to further
improve efficacy in patients receiving preoperative CRT.
Oxaliplatin (Eloxatin
s; Sanofi-Aventis, Bridgewater, NJ, USA) is
an ideal candidate for inclusion into neoadjuvant CRT regimens
because of its radiosensitising capabilities and synergy with
fluoropyrimidines.
Capecitabine has been tested in combination with oxaliplatin
and radiotherapy in several different regimens (for review see
Glynne-Jones et al, 2006a). These include continuous capecitabine
(7 days per week) with oxaliplatin given on days 1 and 29
(Glynne-Jones et al, 2006c), continuous capecitabine (5 days per
week) with weekly doses of oxaliplatin (Machiels et al, 2005;
Rutten et al, 2006) and discontinuous capecitabine (days 1–14 and
22–35) with oxaliplatin on days 1, 8, 22 and 29 (Roedel et al, 2003,
2007). The aim of the present multicentre phase II study was to
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sevaluate the efficacy, tolerability and feasibility of preoperative
capecitabine plus oxaliplatin in combination with radiotherapy as
described by Roedel et al (2003, 2007), and to investigate the
contribution of an additional single cycle of neoadjuvant
capecitabine and oxaliplatin (XELOX regimen) (Dı ´az-Rubio et al,
2002; Cassidy et al, 2004) before the start of radiotherapy.
MATERIALS AND METHODS
Patient population
Patients entering the study had histologically confirmed rectal
adenocarcinoma. Evidence of T3 or T4 disease with or without
perirectal nodal involvement by endorectal ultrasound or magnetic
resonance imaging (MRI) of the pelvis was required. Further
inclusion criteria were an Eastern Cooperative Oncology Group
performance status 0–2 and adequate haematological (neutrophils
X1.5 10
9l
 1 and platelets X100 10
9l
 1), renal (calculated
creatinine clearance 450mlmin
 1) and liver function (serum
bilirubin p1.5 upper limit of normal range, liver transaminase or
alkaline phosphatase concentrations p2.5 upper limit of normal
range). No upper age limit was defined.
Exclusion criteria were metastatic disease, previous chemo-
therapy for colorectal cancer or prior radiotherapy to the pelvis,
history of another malignancy within the last 5 years, any
contraindication to radiotherapy, clinically significant cardiac
disease, malabsorption syndrome, peripheral neuropathy Xgrade
1 according to National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI CTC version 3.0), serious
uncontrolled infection, concomitant treatment with any nucleoside
analogue, known dihydropyrimidine dehydrogenase deficiency
and psychiatric disorders or conditions interfering with comp-
liance for oral drug intake. Pregnant or lactating woman were
excluded.
All patients provided written informed consent. The study
protocol was approved by a local independent ethics committee
and conducted in accordance with the Declaration of Helsinki.
Pretreatment evaluation
Before study entry, all patients were assessed by a multidiscipli-
nary team comprising medical, radiation and surgical oncologists,
gastroenterologists and radiologists. Patients underwent a medical
history, physical examination, biopsy, ECG and staging studies
(chest X-ray, abdominal–pelvis computed tomography scan,
colonoscopy and endorectal ultrasound). Pelvic MRI was optional
but recommended for all patients with low-lying or T4 tumours.
Complete laboratory tests included a full blood count, electrolytes,
creatinine, liver transaminases, alkaline phosphatase, total
bilirubin and carcinoembryonic antigen measurement.
Treatment
Radiotherapy Megavoltage equipment was used with 6–18MV.
Radiotherapy was delivered through three to four portal fields to
the tumour and lymphonodal regions, and perirectal soft tissue
structures at risk of microscopic disease. All patients received
45Gy, with a daily fraction of 1.8Gy given 5 days per week for 5
consecutive weeks. If treatment was interrupted, the dose was
increased by 1–2 fractions.
Chemotherapy Treatment consisted of a single cycle of XELOX
(oral capecitabine 1000mgm
 2 twice daily on days 1–14 plus a 2-h
intravenous infusion of oxaliplatin 130mgm
 2 on day 1), followed
by CAPOX combined with RT (capecitabine 825mgm
 2 twice
daily on days 22–35 and 43–56, and oxaliplatin 50mgm
 2 on days
22, 29, 43 and 50; Figure 1). Chemotherapy and radiotherapy were
interrupted if grade 3 or 4 toxicity was encountered (except for
anaemia). Study treatment was restarted when toxicity had
resolved to grade p1. Dose reductions were required after grade
3–4 toxicity. If treatment was delayed for longer than 3 weeks, the
patient was withdrawn from the study.
Surgery Five to six weeks after completion of CRT, total
mesorectal excision (TME) with sphincter preservation was
performed whenever feasible according to standardised technique
as the preferred type of radical resection. Assessment of the
intended surgical procedure (TME or abdominoperineal resection)
was performed by the treating surgeon before registration.
Administration of adjuvant chemotherapy was left to the treating
oncologist’s discretion.
Evaluation of efficacy and safety
The extent of residual tumour in the resected specimen was
classified according to the TNM staging system of the American
Joint Committee on Cancer/International Union Against Cancer
(AJCC/UICC). Semiquantitative evaluation of histological regres-
sion was performed according to the grading criteria established
by Mandard et al (1994) and Dworak et al (1997) in oesophageal
  Radiotherapy
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Figure 1 Neoadjuvant chemotherapy and concomitant chemoradiation regimen.
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scarcinomas, which was subsequently adapted by Bouzourene et al
(2002) (see Table 1 for summary).
At each site, one preselected pathologist evaluated the tumour
tissue of all patients participating in the study. A second-opinion
pathology review was performed in all tumours categorised as
Dworak grade 2 or 3 by a pathologist from another centre
participating in the study.
Safety was assessed through documenting adverse events and
clinical laboratory tests performed at screening, during treatment
and the surgery period. Adverse events were graded using NCI
CTC version 3.0.
Statistical analysis
The intent-to-treat population (ITT) consisted of all patients who
received at least one dose of study medication whether or not they
were eligible. All efficacy analyses were performed on this
population. Patients not undergoing surgery or who were not
evaluable for response were considered nonresponders. The safety
population consisted of patients who received at least one dose of
any study drug and who had a baseline assessment and at least one
safety follow-up.
The primary end point was pathological complete tumour
response (pCR) prospectively defined as grade 3 or 4 according to
the Dworak classification (DC) system (Dworak et al, 1997). The
pCR rate was presented with 95% confidence intervals (CIs) using
the Pearson–Clopper method. Secondary end points were rate of
sphincter preservation, R0 resection in patients with T4 tumours,
downstaging (defined as a decrease of X1 point(s) in T and/or N
value) and safety.
An exploratory analysis using the Fisher exact test was
performed to test for an association between the presence and
absence of a complete tumour response (DC grade 3/4 vs 0/1/2),
and site, location and size of primary tumour at screening, u/
cTNM classification at screening, time between radiotherapy and
surgery (p40 vs 440 days), age (p60 vs 460 years) and
treatment-related lymphocytopaenia.
This study was designed as a one-stage phase II trial using pCR
rate as the primary efficacy criterion. A pCR of 22% was
considered acceptable and a rate of p7% was ruled out as futile.
With a total of 48 evaluable patients (and a response rate of at least
22%), a power of 86% and a type-I error of 4.8% was achieved. The




A total of 60 patients were enrolled between March 2005 and July
2006 from six cancer centres in Switzerland. Patient characteristics
are summarised in Table 2. All 60 patients were included in the
safety and ITT populations, including 2 patients who were
ineligible (one patient because of cT2 rectal cancer, and the other
patient because of an urothelial cancer 4 years before the start of
the study). Fifty-eight patients (97% of all recruited patients)
received CRT and underwent surgery; one patient withdrew
consent and one patient died prior to surgery.
Dose intensity and safety
Fifty-five patients (92%) received all three cycles of capecitabine
(mean relative dose intensity 97%), and 52 patients (87%) received
all five planned oxaliplatin doses (mean relative dose intensity
97%). The mean relative dose intensity for capecitabine was 98%
during XELOX and 96% during CAPOX-RT. For oxaliplatin, the
mean relative dose intensity was 99% during XELOX and 93%
during CAPOX-RT. Fifty-six patients (93%) received at least 25
fractions (45Gy) of radiotherapy as planned.
Table 3 summarises grade 3/4 treatment-related nonhaemato-
logical toxicities presented per treatment regimen (XELOX vs
CAPOX-RT). The most frequently occurring grade 3/4 adverse
event was diarrhoea (20%); all other grade 3/4 events were
uncommon (p5%). No grade 3/4 haematological toxicity was
observed, except for lymphocytopaenia (43%). At least one serious
Table 2 Patient characteristics (N¼60)





Median (range) 61 (35–76)
u/cTNM classification
T stage 2 1 2
T stage 3 53 88
T stage 4 6 10
N stage 0 13 22
N stage 1 44 73
N stage 2 3 5
Location of tumour
a
Lower rectum (0–5cm) 22 37
Middle rectum (5.1–10cm) 30 50
Upper rectum (10.1–12cm) 17 28
Size of primary tumour (mm)
Median (range) 50 (16–140)
Infiltration of sphincter muscle 6 10
Intended type of surgery
Total mesorectal excision 46 77
Abdominoperineal resection 14 23
aMore than one location per patient possible.
Table 1 Histological tumour regression grading systems
Grade Definition
Dworak et al (1997)
0 No regression
1 Dominant tumour mass with obvious fibrosis and/or vasculopathy
2 Dominantly fibrotic changes with few tumour cells or groups
(easy to find)
3 Very few (difficult-to-find microscopically) tumour cells in fibrotic tissue
with or without mucous substance
4 No tumour cells, only fibrotic mass (total regression or response)
Mandard et al (1994) (adapted by Bouzourene et al, 2002)
5 Absence of regressive changes
4 Residual cancer outgrowing fibrosis
3 Increase in the number of residual cancer cells, but fibrosis still
predominant
2 Presence of rare residual cancer cells scattered through the fibrosis
1 Complete regression, absence of histologically identifiable residual
cancer and fibrosis extending through the different layers of the rectal
wall, with or without granuloma
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sadverse event was recorded in eight patients (13%) during the
study. A total of 12 serious adverse events (20%) were reported, the
most common of which were diarrhoea (n¼5) and colitis or
proctitis (n¼2). One patient developed severe neutropaenic
infection and died on day 19 after the start of neoadjuvant
XELOX. Four patients (7%) had one adverse event leading to
discontinuation of capecitabine, and three patients (5%) had
adverse events leading to discontinuation of oxaliplatin. No patient
required discontinuation of radiotherapy.
Efficacy and surgical parameters
Surgery was performed in a total of 58 patients (TME in 47 patients
(81%), abdominoperineal extirpation in 9 patients (16%) and other
type of surgery in 2 patients (3%)). The median time between the
end of radiotherapy and surgery was 42 days (range: 24–59 days).
In 57 patients (98%), including all 5 patients with c/uT4 tumours,
R0 resection was achieved and sphincter preservation was achieved
in 49 patients (84%).
Comparing the baseline tumour stage with the pathological stage
in the ITT population, downstaging with respect to tumour stage
was observed in 28 (47%) patients, and downstaging with respect
to nodal stage was observed in 29 (48%) patients. A detailed
analysis is shown in Table 4.
In the ITT population, complete tumour regression (ypT0 N0,
DC regression grade 4) was achieved in seven patients. An
additional seven patients showed near-complete regression (DC
regression grade 3) with only very few detectable tumour cells as
assessed by two independent pathologists. According to predefined
criteria, the pCR rate was therefore 23% (95% CI: 13–36%). The
corresponding pCR rate according to the Mandard regression
grading system (grades 1 and 2) was 27% (grade 1, seven patients;
grade 2, nine patients).
A second-opinion review of all specimens rated as DC grade 2 or
3 was necessary in 33 cases (57%). After the second opinion, the
final DC grading remained the same in 27 cases (82%), down-
grading was deemed necessary in 5 cases (15%) and upgrading in 1
case (3%). Both tumour regression scales were compared using
the final DC grades and Mandard grades. The scales seemed
to correspond well; all patients with DC grade 0 reported
Mandard-tumour regression (M-TR) grade 5, 90% of patients
with DC grade 1 reported M-TR grade 4, 74% of patients with DC
grade 2 reported M-TR grade 3, 86% of patients with DC grade 3
reported M-TR grade 2 and all patients with DC grade 4 reported
M-TR grade 1.
According to an exploratory subgroup analysis, only upper
location of the primary tumour (between 10 and 12cm from anal
verge) was found to be negatively correlated with pCR
(P¼0.0504).
DISCUSSION
Pathological complete tumour response rates between 10 and 30%
have been observed with combined preoperative chemotherapy
and radiotherapy protocols. Pathological complete tumour
response is a reliable and reproducible surrogate for tumour
response and is linked to improved outcome (Roh et al, 2004;
Roedel et al, 2005). Although achievement of a pCR is not the
primary goal of neoadjuvant therapy, it has become a commonly
used end point in many phase II trials aiming to improve the
efficacy of rectal cancer treatment.
Table 3 Most frequently reported nonhaematological treatment-related adverse events (N¼60)
Toxicity according to NCI CTC grade (% of patients)
Cycle 1 (XELOX pre-radiotherapy) Cycles 2 and 3 (CAPOX radiotherapy)
Adverse event 1/2 3 4 1/2 3 4
Diarrhoea 12 10 — 38 10 —
Nausea/vomiting 29 3 — 15 — —
Mucositis — 2 — 27 3 —
Bleeding 2 — — 3 2 —
Constipation 7 — — 3 — —
Pain 7 3 — 40 2 —
Fatigue 15 2 — 28 — —
Infection — — 2 12 — —
Hypokalaemia — 2 — — 2 —
Anorexia 6 2 — 8 2 —
Neuropathy 27 — — 30 — —
Dysuria 5 — — 32 — —
Syncope — 2 — — — —
Dyspnoea 3 — — 3 2 —
Hand–foot syndrome 2 — — 6 2 —
Dermatitis 3 — — 3 — —
Rash 3 — — 3 — —
Thrombosis — — — — 3 —
NCI CTC¼National Cancer Institute Common Terminology Criteria.
Table 4 Preoperative T/N stage compared with pathological T/N stage
(N¼58)
Baseline
staging pT0 pTis pT1 pT2 pT3 pT4 pN0 pN1 pN2 pNx
u T 2 ——1———————
u T 3 5 1 11 52 82————
u T 4 1—— 3 1—————
u N 0 —————— 7 3 2 1
u N 1 ——————2 8 6 7 1
u N 2 —————— 1— 2 —
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sIn the present trial, we are able to demonstrate a pCR in 23% of
patients, defined as grades 3 and 4 according to the Dworak
classification (Dworak et al, 1997) following preoperative therapy
with a single cycle of XELOX and two further cycles of CAPOX
given with radiotherapy. Recently, several different tumour
regression scales (Mandard et al, 1994; Dworak et al, 1997;
Bouzourene et al, 2002; Wheeler et al, 2004) have been proposed
for the measurement of regression after preoperative therapies
independent of the ypTNM stage. Besides several differences in
categorisation of tumour regression, all of the scales acknowledge a
distinctive group of tumours with only microscopic foci of
remaining tumour cells. We have grouped patients with sterilised
primary tumours and lymph nodes (DC grade 4) together with DC
grade 3 tumours. This is based on the observation that single
residual tumour cells confer a significantly lower local relapse rate
and a better prognosis (Wheeler et al, 2004) than tumours with
remaining dominant disease.
The second-opinion review was used for all specimens rated to
be either DC grade 2 or 3 by the first pathologist. A high
concordance rate between independent pathologists of 82%
suggests a reasonable capability to discriminate between very few
and difficult-to-find tumour cells (DC grade 3) from easy-to-find
few tumour cells or groups of tumour cells (DC grade 2). In
addition, applying the regression grading classification of
Mandard et al (1994) adapted for rectal cancer (Bouzourene
et al, 2002) and combining Mandard’s grade 1 (absence of residual
tumour cells) and grade 2 (rare residual tumour cells), complete
tumour response was achieved in 27% of patients. These almost
identical results from two different scoring systems indicate a high
reproducibility in defining near-complete and complete sterilisa-
tion of tumour cells.
Furthermore, and an important point with regard to prognosis,
we observed nodal downstaging in 48% of patients. The number of
tumour-infiltrated lymph nodes (ypN status) following preopera-
tive radiochemotherapy is a strong and independent prognostic
factor for survival. Sterilising lymph nodes reflects the impact of
effective neoadjuvant treatment and consistently translates into
improved long-term outcome (Bouzourene et al, 2002; Chan et al,
2005; Chapet et al, 2005; Roedel et al, 2005).
In 98% of the 58 patients who underwent surgery and in all
patients with T4 rectal cancer, R0 resection was possible. Sphincter
preservation was achieved in 84% of patients. This appears
remarkable as 35% of our patients had low-lying tumours (0–5cm
from anal verge).
The most common nonhaematological toxicity in our trial was
grade 3 or 4 diarrhoea, which occurred overall in 20% of patients
(10% during XELOX and 10% during CAPOX-RT). This rate is
slightly higher than that reported by Roedel et al (2003, 2007) and
suggests that the additional cycle of XELOX increased the toxicity
of preoperative CRT. All other toxicities were in the range of other
trials with the exception of grade 3 or 4 lymphocytopaenia.
Lymphocytopaenia is a negative prognostic factor in cancer
patients and can be induced by either chemotherapy or pelvic
radiotherapy. Decline in total lymphocyte counts is obviously an
underreported toxicity and seems to be negatively correlated with
tumour regression following pelvic radiotherapy (Lissoni et al,
2005).
The addition of a single chemotherapy cycle before CRT does
not appear to have substantially enhanced the overall antitumour
activity and should, therefore, not be considered as an important
treatment element. In our trial, we added this chemotherapy cycle
primarily to assure early start of therapy. Even though many
patients reported improvement in symptoms before starting CRT
(data not shown), we did not consider achieving a relevant
downsizing effect with a single chemotherapy cycle.
The use of neoadjuvant chemotherapy prior to preoperative
CRT in rectal cancer patients is a matter of debate (Glynne-Jones
and Sebag-Montefiore, 2006; Glynne-Jones et al, 2006b) primarily
because satisfactory local control rates can be achieved with
preoperative CRT alone. Chau et al (2006) questioned this position
by adding four cycles of neoadjuvant capecitabine and oxaliplatin
before CRT with capecitabine in their trial. Most patients (86%)
had symptomatic responses, and the radiological response rate
measured by MRI was 88%. Pathological complete tumour
response was achieved in 24% of patients, which is clearly
superior to the 11% DC regression grade 4 in our trial. However,
4 out of 77 patients died during neoadjuvant chemotherapy. In the
absence of a randomised phase III trial proving superior outcome,
the addition of primary chemotherapy to CRT should be only used
in the context of clinical trials.
A different treatment strategy, in an attempt to increase the
quantity of systemic treatment, was studied by Roedel et al (2007).
After preoperative capecitabine/oxaliplatin radiotherapy, 60%
of patients received all four cycles of adjuvant capecitabine/
oxaliplatin underlining the feasibility of delivering adequate doses
of postoperative combination chemotherapy in rectal cancer
patients.
In conclusion, we demonstrated that preoperative XELOX
followed by CAPOX-RT is feasible with manageable toxicity and
results in encouragingly high rates of pCR, R0 resection, sphincter
preservation and tumour downstaging in patients with locally
advanced rectal cancer. More importantly, we were able to
replicate, and thus confirm the findings from Roedel et al (2003,
2007) in a multicentre setting in Switzerland.
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